Visiongain has published a new report entitled Biobanking Market Report 2025-2035 (Including Impact of U.S. Trade Tariffs): Forecasts by Product and Services ((Equipment (Storage Equipment, Sample Analysis Equipment, Sample Processing Equipment, Sample Transport Equipment), Consumables (Storage Consumables, Analysis Consumables, Processing Consumables, Collection Consumables), Services (Storage Services, Processing Services, Transport Services, Supply Services), Software)), by Storage Type (Automated Storage, Manual Storage), by Ownership (National/Regional Agencies, Universities, Non-profit, Private), by Sample (Blood Products, Human Tissues, Nucleic Acids, Cell Lines, Biological Fluids), by Application (Regenerative Medicine, Life Science Research, Clinical Research), by End-users (Pharmaceutical & Biotechnology Companies, CROs, Academic & Research Institutes, Hospitals), AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies.

The Biobanking market is estimated at US$83.1 billion in 2025 and is projected to grow at a CAGR of 8.8% during the forecast period 2025-2035.

Impact of the U.S. Trade Tariffs on the Global Biobanking Market 

The escalation of U.S. trade tariffs on laboratory equipment, cold-chain systems, stainless-steel biorepository infrastructure, and digital hardware is reshaping cost structures across the global biobanking market. Higher import duties on freezers, cryogenic vessels, sensors, and automation components sourced from China and Southeast Asia are increasing capital expenditure for biobanks by 8–15%, particularly impacting small and mid-sized facilities. These tariffs are also delaying procurement cycles, extending installation timelines, and pushing operators to reassess suppliers, spare-parts availability, and long-term maintenance costs. As U.S. buyers shift toward non-tariff markets such as South Korea, Germany, and domestic manufacturers, global supply chains are experiencing a gradual re-balancing. For service-led biobanking models, increased equipment costs are translating into higher storage and processing fees. Over the long term, persistent tariffs may accelerate adoption of automation-light workflows, refurbished systems, and multi-vendor sourcing strategies to maintain operational continuity and manage pricing pressure.

Growing Regenerative Medicine and Real-World Evidence Needs, Supported Bb Data Partnerships, are Boosting New Revenue Opportunities for Biobanks

Regenerative medicine, real-world evidence generation, and cross-sector data partnerships are opening substantial new revenue opportunities for biobanks, further amplifying global market growth. The rapid expansion of cell- and gene-therapy pipelines has intensified demand for highly characterised, ethically sourced, and traceable biospecimens—elevating biobanks from passive storage centres to essential enablers of next-generation therapeutic development. Population-level biobanking is also expanding as health systems pursue longitudinal datasets, real-world evidence, and AI-driven biomarker discovery, driving the need for organised repositories capable of supporting multi-omics analysis at scale.

Collaborations between hospitals, biotech firms, CROs, and government agencies are generating recurring income streams through processing services, cold-chain logistics, and data-linked sample access models. Strengthening governance and standardisation, once obstacles, are now enabling broader global cooperation. In October 2025, Abu Dhabi Biobank partnered with the American Society of Regenerative Medicine to host the Regenerative Medicine Congress in Dubai—highlighting its role as a regional leader with the largest hybrid cord blood banking facility. Collectively, these forces are expanding commercial service lines and accelerating the upward trajectory of the biobanking market.

How will this Report Benefit you?

Visiongain’s 355-page report provides 121 tables and 182 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the Biobanking market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for Biobanking. Get financial analysis of the overall market and different segments including type, phase and capture higher market share. We believe that there are strong opportunities in this fast-growing Biobanking market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report will help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.

What are the Current Market Drivers?

Rising Demand for Population-Scale Genomic and Proteomic Programs is Accelerating Global Investment in High-Capacity Biobanks

The rapid expansion of national genome initiatives, longitudinal cohort studies, and large-scale proteomic mapping programmes is creating unprecedented demand for highly organised, high-integrity biobanking infrastructure. Governments and research institutions are intensifying investments in biobanks capable of handling millions of biospecimens collected over years, each requiring standardised storage conditions, rich metadata capture, and secure, interoperable data pipelines. These population cohorts rely heavily on biobank-supported sample integrity to identify disease-associated variants, model long-term health trajectories, and validate therapeutic targets at scale.

As multi-year, biobank-enabled research becomes central to preventive healthcare and digital epidemiology strategies, countries are dedicating significant capital to expanding ultra-low-temperature storage systems, automated retrieval technologies, and cloud-connected informatics platforms. This sustained public investment serves as a strong structural driver, supporting continuous sample inflows, stable funding, and long-term demand across biobanking equipment, consumables, and specialised services.

In July 2025, this trend was exemplified by the CSIR-Institute of Genomics and Integrative Biology (IGIB), which launched India’s first National Biobank under the Phenome India project. The facility is building a comprehensive longitudinal database by integrating genomic, clinical, and lifestyle information from 10,000 participants nationwide. Modelled on the UK Biobank, the initiative reinforces India’s biobanking capacity to support personalised medicine, AI-enabled diagnostics, and research into complex diseases such as diabetes, cancer, and cardiovascular disorders—further highlighting the strategic importance of advanced biobanks in population-scale science.

Biobanking Enters the 4.0 Era as Biospecimens Become High-Value Digital Assets Driving Precision Medicine

Biobanking demand is accelerating as the sector advances into the Biobanking 4.0 era, where biospecimens function as high-value digital assets powering multi-omics research, AI model development, and precision-medicine pipelines. The industry is shifting from traditional storage facilities to digitally integrated research engines, with biospecimens recognised not only as biological materials but also as sources of rich, structured data. This evolution is fuelled by growing requirements for comprehensive, multi-layered datasets spanning genomics, transcriptomics, proteomics, imaging, and clinical informatics.

Modern biobanks are adopting cyber-physical architectures that incorporate automation, smart sensors, real-time environmental monitoring, advanced LIMS platforms, and AI-enabled quality systems. Consequently, market growth is increasingly defined not by physical freezer capacity but by the ability to generate, standardise, and integrate high-fidelity data linked to each sample. This transition is unlocking new commercial opportunities in analytical services, data-licensing models, and multi-omics research support, reinforcing the sector’s upward trajectory.

In July 2025, UK Biobank announced a three-year programme to develop a multi-modal AI foundation model combining genomic data, medical imaging, and electronic health records. The initiative exemplifies the Biobanking 4.0 paradigm by transforming biospecimens into digitally interoperable research engines capable of enabling predictive disease modelling and clinical risk forecasting. It sets a new benchmark for how biobanks can drive precision-medicine innovation through structured, integrated data ecosystems.

Where are the Market Opportunities?

Advanced Analytics and Data-Linked Biospecimens Are Creating New Revenue Pathways as Biobanks Evolve into Computational Research Hubs

Modern biobanks are increasingly integrating genomic, proteomic, imaging, and electronic health-record data, transforming into advanced computational centres that support refined patient stratification, disease modelling, and predictive analytics. AI and machine learning are amplifying the value of biospecimen collections by uncovering biomarkers, mapping genetic variations, and accelerating early-stage drug discovery. This data-driven model is unlocking new commercial avenues such as multi-omics research services, data-licensing frameworks, retrospective safety analyses, and precision-medicine partnerships.

However, these opportunities also elevate governance requirements. Protecting sensitive patient information, ensuring interoperability across biobanks, and preserving sample integrity through validated storage, tracking, and chain-of-custody systems remain critical challenges. Compliance with international standards—ISO, ICH, cGMP, GDPR—continues to differentiate biobanks seeking global collaborations. As demand for high-quality, richly annotated biospecimens increases, pharmaceutical companies and research organisations are outsourcing storage and processing to specialised biorepositories, driving operational efficiency and sustained market growth.

In June 2025, Elucidata partnered with Sapien Biosciences—India’s largest commercial biobank with over 300,000 patient samples—to convert biospecimen assets into AI-ready multimodal data products. Sapien’s repository spans oncology, cardiology, autoimmune, neurology, and rare diseases, increasingly linked with digitised histopathology images and genomic profiles. The collaboration centres on AI-assisted harmonisation, predictive modelling, and synthetic dataset generation, directly reinforcing the industry’s shift toward biobanks as computational research engines.

Expansion of Biobank-enabled Real-World Evidence (RWE) Frameworks Ii Creating New Revenue Pathways for Integrated Biospecimen–Data Platforms

The growing use of real-world evidence (RWE) in regulatory decision-making, post-marketing safety assessments, and precision-medicine development is creating a significant commercial opportunity for biobanks. As health systems shift toward outcomes-based evaluation, demand is rising for biospecimens that are linked to longitudinal clinical records, treatment outcomes, imaging datasets, and multi-omics profiles. Biobanks equipped with integrated data infrastructures can monetise these assets by enabling retrospective analyses, comparative-effectiveness studies, adverse-event investigations, and advanced patient-stratification models.

This evolution positions biobanks not as passive storage facilities but as critical evidence-generation partners for pharmaceutical, biotechnology, and diagnostics companies. The ability to deliver curated, ethically governed biospecimen–data packages opens new high-value service offerings—including data-access agreements, cohort-matching solutions, and analytics support—allowing digitally mature biobanks to secure recurring, premium revenue streams within the expanding RWE ecosystem.

Competitive Landscape

The major players operating in the Biobanking market are Azenta Inc., BD, BioIVT, Boca Biolistics, Charles River Laboratories International, Inc., Cryoport, Inc., CTIBiotech, Hamilton Company, ISENET, Labcorp, Merck KGaA, PHC Holdings Corporation, ProteoGenex Inc., QIAGEN, SciSafe, STEMCELL Technologies, Tecan Trading AG, Thermo Fisher Scientific Inc., and US Biolab Corporation among others. These major players operating in this market have adopted various strategies comprising M&A, investment in R&D, collaborations, partnerships, regional business expansion, and new product launch.

Recent Developments

• In July 2025, UK Biobank announced a three-year programme to develop a multi-modal AI foundation model combining genomic data, medical imaging, and electronic health records. The initiative exemplifies the Biobanking 4.0 paradigm by transforming biospecimens into digitally interoperable research engines capable of enabling predictive disease modelling and clinical risk forecasting. It sets a new benchmark for how biobanks can drive precision-medicine innovation through structured, integrated data ecosystems.
• On 4^th June 2025, Elucidata and Sapien Biosciences, India’s first and largest commercial biobank with 300,000+ patient samples founded in partnership with Apollo Hospitals, today announced a strategic partnership to convert Sapien’s extensive biobank assets into AI-ready, multimodal data products for use in drug and diagnostic development.
• On 23^rd January 2025, Azenta, Inc. announced that it was selected as the technology provider by UK Biocentre as they expand their large-scale sample storage in support of the preservation of internationally significant sample collections. This new system is in addition to the seven Azenta BioArc™ Flex™ automated sample store systems already in place at the facility.
• On 9^th January 2025, Thermo Fisher Scientific Inc. announced the UK Biobank Pharma Proteomics Project (UKB-PPP) has selected its Olink® Explore Platform to support the world’s largest human proteomics study of its kind. UKB-PPP aims to analyze more than 5,400 proteins from 600,000 samples to fuel the discovery of new protein biomarkers that can be used to predict, diagnose and treat diseases.
• On 3^rd May 2024, Hamilton Storage Technologies, Inc., announced that four high-capacity Hamilton BiOS® automated storage systems will be installed in UK Biobank’s new Manchester Science Park headquarters. UK Biobank is the world’s most comprehensive source of health data available for research, housing a vast and continuously growing dataset of biological, health, and lifestyle information collected over 15 years from half a million UK volunteers. Over 30,000 researchers from more than 90 countries are registered to use this de-identified data to better understand the causes of disease and drive the discovery of new preventions, treatments, and cures.

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to contactus@visiongain.com or call +44 207 336 6100.

About Visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.